Please use this identifier to cite or link to this item:
Title: A cost-effectiveness analysis of genomic sequencing in a prospective versus historical cohort of complex pediatric patients.
Austin Authors: Yeung, Alison;Tan, Natalie B;Tan, Tiong Y;Stark, Zornitza;Brown, Natasha;Hunter, Matthew F;Delatycki, Martin B ;Stutterd, Chloe;Savarirayan, Ravi;Mcgillivray, George;Stapleton, Rachel;Kumble, Smitha;Downie, Lilian;Regan, Matthew;Lunke, Sebastian;Chong, Belinda;Phelan, Dean;Brett, Gemma R;Jarmolowicz, Anna;Prawer, Yael;Valente, Giulia M ;Smagarinsky, Yana;Martyn, Melissa;McEwan, Callum;Goranitis, Ilias;Gaff, Clara;White, Susan M
Affiliation: Department of Pediatrics, University of Melbourne, Melbourne, Australia
Monash Genetics, Monash Health, Melbourne, Australia
Victorian Clinical Genetics Services, Murdoch Children's Research Institute, Melbourne, Australia
Murdoch Children's Research Institute, Melbourne, Australia
Australian Genomics Health Alliance, Melbourne, Australia
Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia
Melbourne Genomics Health Alliance, Melbourne, Australia
Clinical Genetics
Department of Pediatrics, Monash University, Melbourne, Australia
Issue Date: Dec-2020
Date: 2020-08-10
Publication information: Genetics in Medicine 2020; 22(12): 1986-1993
Abstract: Cost-effectiveness evaluations of first-line genomic sequencing (GS) in the diagnosis of children with genetic conditions are limited by the lack of well-defined comparative cohorts. We sought to evaluate the cost-effectiveness of early GS in pediatric patients with complex monogenic conditions compared with a matched historical cohort. Data, including investigation costs, were collected in a prospective cohort of 92 pediatric patients undergoing singleton GS over an 18-month period (2016-2017) with two of the following: a condition with high mortality, multisystem disease involving three or more organs, or severe limitation of daily function. Comparative data were collected in a matched historical cohort who underwent traditional investigations in the years 2012-2013. GS yielded a diagnosis in 42% while traditional investigations yielded a diagnosis in 23% (pā€‰=ā€‰0.003). A change in management was experienced by 74% of patients diagnosed following GS, compared with 32% diagnosed following traditional investigations. Singleton GS at a cost of AU$3100 resulted in a mean saving per person of AU$3602 (95% confidence interval [CI] AU$2520-4685). Cost savings occurred across all investigation subtypes and were only minimally offset by clinical management costs. GS in complex pediatric patients saves significant costs and doubles the diagnostic yield of traditional approaches.
DOI: 10.1038/s41436-020-0929-8
ORCID: 0000-0002-5793-6016
Journal: Genetics in Medicine
PubMed URL: 32773771
Type: Journal Article
Subjects: cost-effectiveness
exome sequencing
genomic sequencing
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Nov 29, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.